Linagliptin

The newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus

Rachael Aletti, Angela Cheng-Lai

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors are some of the newest medications in our armamentarium for the management of type 2 diabetes mellitus. Through inhibition of the DPP-4 enzyme, these agents increase the amount of circulating incretin hormones, leading to an increase in insulin release and a suppression of glucagon secretion. Linagliptin is the third DPP-4 inhibitor approved by the Food and Drug Administration in the United States. It has been studied as monotherapy and as an adjunctive therapy to other oral agents in a dual or triple combination regimen. Linagliptin lowers glycosylated hemoglobin by about 0.4% when used as monotherapy and by about 0.5% to 1.1% when used in combination with other oral antihyperglycemic agents. Since linagliptin is mostly eliminated via the enterohepatic system (80%) and not to a significant extent through renal excretion, dosage adjustment is not necessary in patients with renal impairment. Linagliptin also has a favorable safety profile; nasopharyngitis is one of the more common observed side effects. Given its encouraging safety and efficacy profile, linagliptin is a good alternative to the other 2 agents in this class, especially for patients with renal impairment. This article provides a review of the pharmacologic and pharmacokinetic properties of linagliptin. The differences among the 3 available DPP-4 inhibitors will also be examined.

Original languageEnglish (US)
Pages (from-to)45-51
Number of pages7
JournalCardiology in Review
Volume20
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Type 2 Diabetes Mellitus
Nasopharyngitis
Dipeptidyl Peptidase 4
Incretins
Kidney
Safety
Glycosylated Hemoglobin A
United States Food and Drug Administration
Glucagon
Hypoglycemic Agents
Linagliptin
Pharmacokinetics
Hormones
Insulin
Enzymes

Keywords

  • diabetes mellitus
  • dipeptidyl peptidase-4 inhibitors
  • incretin therapy
  • linagliptin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Linagliptin : The newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. / Aletti, Rachael; Cheng-Lai, Angela.

In: Cardiology in Review, Vol. 20, No. 1, 01.2012, p. 45-51.

Research output: Contribution to journalArticle

@article{0a34910320ca448c93cdb1b10808ec03,
title = "Linagliptin: The newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus",
abstract = "Dipeptidyl peptidase-4 (DPP-4) inhibitors are some of the newest medications in our armamentarium for the management of type 2 diabetes mellitus. Through inhibition of the DPP-4 enzyme, these agents increase the amount of circulating incretin hormones, leading to an increase in insulin release and a suppression of glucagon secretion. Linagliptin is the third DPP-4 inhibitor approved by the Food and Drug Administration in the United States. It has been studied as monotherapy and as an adjunctive therapy to other oral agents in a dual or triple combination regimen. Linagliptin lowers glycosylated hemoglobin by about 0.4{\%} when used as monotherapy and by about 0.5{\%} to 1.1{\%} when used in combination with other oral antihyperglycemic agents. Since linagliptin is mostly eliminated via the enterohepatic system (80{\%}) and not to a significant extent through renal excretion, dosage adjustment is not necessary in patients with renal impairment. Linagliptin also has a favorable safety profile; nasopharyngitis is one of the more common observed side effects. Given its encouraging safety and efficacy profile, linagliptin is a good alternative to the other 2 agents in this class, especially for patients with renal impairment. This article provides a review of the pharmacologic and pharmacokinetic properties of linagliptin. The differences among the 3 available DPP-4 inhibitors will also be examined.",
keywords = "diabetes mellitus, dipeptidyl peptidase-4 inhibitors, incretin therapy, linagliptin",
author = "Rachael Aletti and Angela Cheng-Lai",
year = "2012",
month = "1",
doi = "10.1097/CRD.0b013e31823a3afc",
language = "English (US)",
volume = "20",
pages = "45--51",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Linagliptin

T2 - The newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus

AU - Aletti, Rachael

AU - Cheng-Lai, Angela

PY - 2012/1

Y1 - 2012/1

N2 - Dipeptidyl peptidase-4 (DPP-4) inhibitors are some of the newest medications in our armamentarium for the management of type 2 diabetes mellitus. Through inhibition of the DPP-4 enzyme, these agents increase the amount of circulating incretin hormones, leading to an increase in insulin release and a suppression of glucagon secretion. Linagliptin is the third DPP-4 inhibitor approved by the Food and Drug Administration in the United States. It has been studied as monotherapy and as an adjunctive therapy to other oral agents in a dual or triple combination regimen. Linagliptin lowers glycosylated hemoglobin by about 0.4% when used as monotherapy and by about 0.5% to 1.1% when used in combination with other oral antihyperglycemic agents. Since linagliptin is mostly eliminated via the enterohepatic system (80%) and not to a significant extent through renal excretion, dosage adjustment is not necessary in patients with renal impairment. Linagliptin also has a favorable safety profile; nasopharyngitis is one of the more common observed side effects. Given its encouraging safety and efficacy profile, linagliptin is a good alternative to the other 2 agents in this class, especially for patients with renal impairment. This article provides a review of the pharmacologic and pharmacokinetic properties of linagliptin. The differences among the 3 available DPP-4 inhibitors will also be examined.

AB - Dipeptidyl peptidase-4 (DPP-4) inhibitors are some of the newest medications in our armamentarium for the management of type 2 diabetes mellitus. Through inhibition of the DPP-4 enzyme, these agents increase the amount of circulating incretin hormones, leading to an increase in insulin release and a suppression of glucagon secretion. Linagliptin is the third DPP-4 inhibitor approved by the Food and Drug Administration in the United States. It has been studied as monotherapy and as an adjunctive therapy to other oral agents in a dual or triple combination regimen. Linagliptin lowers glycosylated hemoglobin by about 0.4% when used as monotherapy and by about 0.5% to 1.1% when used in combination with other oral antihyperglycemic agents. Since linagliptin is mostly eliminated via the enterohepatic system (80%) and not to a significant extent through renal excretion, dosage adjustment is not necessary in patients with renal impairment. Linagliptin also has a favorable safety profile; nasopharyngitis is one of the more common observed side effects. Given its encouraging safety and efficacy profile, linagliptin is a good alternative to the other 2 agents in this class, especially for patients with renal impairment. This article provides a review of the pharmacologic and pharmacokinetic properties of linagliptin. The differences among the 3 available DPP-4 inhibitors will also be examined.

KW - diabetes mellitus

KW - dipeptidyl peptidase-4 inhibitors

KW - incretin therapy

KW - linagliptin

UR - http://www.scopus.com/inward/record.url?scp=83155190231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83155190231&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e31823a3afc

DO - 10.1097/CRD.0b013e31823a3afc

M3 - Article

VL - 20

SP - 45

EP - 51

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 1

ER -